CLINICAL TRIALS AND OBSERVATIONS

Nonsteroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal hematodiaphyseal dysplasia

Timothy J. Brown,^{1,*} Neil Barrett,^{2,*} Hu Meng,^{3,*} Emanuela Ricciotti,^{3,4} Ciara McDonnell,⁵ Andrew Dancis,¹ Julianne Qualtieri,⁶ Garret A. FitzGerald,³ Melanie Cotter,^{2,†} and Daria V. Babushok^{1,7,†}

¹ Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Paediatric Haematology, Children's Health Ireland at Temple Street/Crumlin, Dublin, Ireland; ³Institute for Translational Medicine and Therapeutics and ⁴Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; ⁵Paediatric Endocrinology, Children's Health Ireland at Temple Street/Crumlin and Discipline of Paediatrics, University of Dublin Trinity College Dublin, Dublin, Ireland; ⁶Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; and ⁷Comprehensive Bone Marrow Failure Center, Children's Hospital of Philadelphia, PA

KEY POINTS

- NSAIDs can normalize hematologic parameters and serum inflammatory markers in patients with Ghosal hematodiaphyseal dysplasia syndrome.
- Prostaglandins and leukotrienes are aberrantly augmented in patients with Ghosal syndrome and are responsive to treatment with NSAIDs.

Advances in genomic diagnostics hold promise for improved care of rare hematologic diseases. Here, we describe a novel targeted therapeutic approach for Ghosal hematodiaphyseal dysplasia, an autosomal recessive disease characterized by severe normocytic anemia and bone abnormalities due to loss-of-function mutations in thromboxane A synthase 1 (*TBXAS1*). TBXAS1 metabolizes prostaglandin H₂ (PGH₂), a cyclooxygenase (COX) product of arachidonic acid, into thromboxane A₂. Loss-of-function mutations in TBXAS result in an increase in PGH₂ availability for other PG synthases. The current treatment for Ghosal hematodiaphyseal dysplasia syndrome consists of corticosteroids. We hypothesize that nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit COX-1 and COX-2, could ameliorate the effects of *TBXAS1* loss and improve hematologic function by reducing prostaglandin formation. We treated 2 patients with Ghosal hematodiaphyseal dysplasia syndrome concerning hematologic parameters and inflammatory markers without adverse events. Mass spectrometry analysis demonstrated that urinary PG metabolites were increased along with proin-

flammatory lipoxygenase (LOX) products 5-hydroxyeicosatetraenoic acid and leukotriene E₄. Our data show that NSAIDs at standard doses surprisingly reduced both COX and LOX products, leading to the resolution of cytopenia, and should be considered for first-line treatment for Ghosal hematodiaphyseal dysplasia syndrome.

Introduction

The growing use of genomic diagnostics holds promise for tailored therapies for rare hematologic disorders. In this study, we describe a treatment that reverses the effects of the underlying genetic abnormality in Ghosal hematodiaphyseal dysplasia syndrome, an autosomal recessive disease caused by inherited loss-of-function mutations in thromboxane A synthase 1 (*TBXAS1*).^{1,2}

Ghosal hematodiaphyseal dysplasia syndrome is characterized by corticosteroid-sensitive normocytic anemia and increased bone density along with diaphyseal dysplasia.^{1,2} Thirty-six cases of Ghosal hematodiaphyseal dysplasia syndrome of varying severities have been reported, most commonly in Middle Eastern, North African, and South Asian individuals; recently, patients who are of North American-European descent have also been identified. Ghosal hematodiaphyseal dysplasia syndrome has been traditionally treated using repeated courses of corticosteroids to maintain adequate hemoglobin levels.¹⁻¹²

Because disruption of *TBXAS1* causes accumulation of arachidonic acid (AA) metabolites due to the rediversion of its prostaglandin H₂ (PGH₂) substrate (Figure 1A), we hypothesized that nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase-1 (COX-1) and COX-2, could ameliorate the effects of *TBXAS1* loss and improve the hematologic function by reducing prostaglandin formation. We administered ibuprofen or aspirin, at doses that inhibit both COX-1 and COX-2, to 2 patients, an adult and a child, with Ghosal hematodiaphyseal dysplasia syndrome. Our data show that COX-1/2



Figure 1. AA metabolism and the clinical characteristics of 2 patients with Ghosal hematodiaphyseal dysplasia syndrome. (A) A schematic diagram of the AA metabolism pathway. AA is released from the membrane phospholipids by PLA₂ and is metabolized by COX-1 and -2 enzymes, (green oval) first into the unstable intermediate metabolite PGG₂, which is converted to PGH2. PGH₂ serves as a substrate for several PG synthases (PGDS, PGES, PGIS, blue ovals) that generate the following proinflammatory PG metabolites: PGD₂, PGE₂, and PGI₂. PGH₂ can also be converted to TXA₂ through the action of thromboxane synthase (red oval), the gene which is mutated in Ghosal hematodiaphyseal dysplasia syndrome. In addition to the COX-1/2 enzymes, AA is metabolized by 5-LOX (blue oval) to generate various products of hydroperoxyeicosatetraenoic acid, including 5-HETE and leukotrienes, for example, LTE₄. (B) Bone marrow biopsy sections for patient 1 have aspiration artifact but show an apparent reduction in marrow cellularity out of proportion to peripheral counts. On the left, H&E-stained section at an original magnification ×10 additionally shows thickened trabeculae (black arrow), and on the right, the H&E-stained sections of the variants in the 2 patients reported in this manuscript (shown in red, above the diagram), and those from 13 sequenced cases previously reported in the literature (shown in blue, below the diagram). Diagram created using Domain Graph (DOG, version 2.0). D (for Case 1) and E (for Case 2), show. H&E, hematoxylin and eosin; 5-LOX, 5-lipooxygenase; PLA₂, phospholipase A₂; TXA₂, thromboxane A₂.

inhibition improves hematologic and inflammatory parameters and should be considered as a first-line treatment for Ghosal hematodiaphyseal dysplasia syndrome.

Study design

After informed consent was obtained, patients were treated with ibuprofen or aspirin as per routine clinical care, independent of each other, at the discretion of their respective treating physicians. Because aspirin is associated with Reye syndrome among children, the pediatric patient received ibuprofen. Eicosanoid analysis from patients and control participants was performed as a part of the ongoing institutional review board– approved studies at the University of Pennsylvania.

Whole exome sequencing (WES) of peripheral blood DNA was performed at clinical genetic testing laboratories (Genome Diagnostics Nijmegen Maastricht, Nijmegen, Netherlands; and Invitae, San Francisco, CA). Mass spectrometry of urinary eicosanoid metabolites, which enables reliable quantitative analysis of systemic eicosanoid formation in vivo, ¹³ was performed using several 24-hour urine collection samples, collected at baseline (for patient 2) and after 3 months of high-dose NSAID treatment, after withholding NSAID for 14 days, and after 3 weeks of low-dose NSAID (for both patients). Results were analyzed using analysis of variance (ANOVA) with a significant *P*-value < .05 (see supplemental Material, available on the *Blood* website).

Results and discussion

Case presentations and genetic diagnosis

Patient 1 A 30-year-old Pakistani male who was born to a consanguineous family was evaluated for life-long normocytic anemia and thrombocytopenia. He had chronic fatigue, joint stiffness, and diarrhea. A bone marrow biopsy at 2 years of age was nondiagnostic. He received ~50 red blood cell transfusions before the age of 7 years. Corticosteroids produced periods of transfusion independence; however, the anemia relapsed after steroid tapering. Two of the patient's siblings died in infancy; 1 of them had a condition resembling his, and the other died of an unspecified neurological disorder.

Laboratory studies revealed normocytic anemia (hemoglobin, 8.5-10.6 g/dL), platelets of 100 to $120 \times 10^3/\mu$ L, and intermittent mild neutropenia with absolute neutrophil count of ~1.2-2.5 × $10^{3}/\mu$ L. Erythrocyte sedimentation rate (ESR) and C-reactive protein level were persistently elevated at 76-111 mm/h and 2.1-3.2 mg/dL, respectively. The erythropoietin level was >741 miU/mL (normal range, 2.6-18.5). Iron levels were normal. Reticulocytes ranged from 88 to $109 \times 10^{3}/\mu$ L (reticulocyte index <2), consistent with hypoproliferative anemia. Two bone marrow biopsies, both technically challenging, showed reduced hematopoietic elements, with orderly normoblastic maturation of evaluable scant erythroid precursors as well as thickened trabeculae and disorganized osteocytes (Figure 1B). Lymphocyte telomere lengths were short for the given age, and chromosome breakage was normal. WES helped identify a likely pathogenic homozygous p.R413Q missense substitution in TBXAS1 (Figure 1C).² The skeletal survey showed cortical thickening of bilateral femoral shafts and proximal humeri, with diffuse osseous sclerosis throughout the spine. Bone density was increased (lumbar spine [LS] L1-L4; Z-score +1.2), consistent with that observed in Ghosal hematodiaphyseal dysplasia syndrome.¹

Patient 2 A previously healthy 3-year-old girl of Filipino descent was found to have severe anemia (hemoglobin, 5.3 g/dL) and thrombocytopenia (platelets, $12 \times 10^3/\mu$ L) during hospitalization for bacterial pneumonia. Normocytic anemia (hemoglobin, 6.0-7.5mg/dL) and thrombocytopenia (platelet range, 60-110 × $10^3/\mu$ L) persisted after resolution of infection, with intermittent neutropenia with the absolute neutrophil count as low as $0.19 \times 10^3/\mu$ L. The reticulocyte count was $34 \times 10^3/\mu$ L (reticulocyte index <2). The ESR was markedly elevated to between 112 and >130 mm/h. Bone marrow was profoundly hypocellular, with fatty replacement and areas of fibrotic stroma containing scattered hematopoietic elements. The karyotype was normal. Paroxysmal nocturnal hemoglobinuria screen, hemoglobin electrophoresis, chromosomal breakage studies, and lymphocyte telomere lengths were unremarkable. Via WES,

we identified a novel, homozygous, likely pathogenic p.R287* *TBXAS1* variant, inherited from her clinically unaffected parents, each heterozygous for the variant. Bone density was markedly increased (LS, L1-L4; Z-score +2.4), consistent with that observed in Ghosal hematodiaphyseal dysplasia syndrome.

Dose-dependent hematologic response and eicosanoid suppression by COX-1/2 inhibitors

Patient 1 was started on aspirin with a dose of 325 mg per day, with normalization of hematologic and inflammatory parameters and improvements in fatigue and joint stiffness after 2 months (Figure 1D). When aspirin was discontinued for 14 days, symptoms recurred and were accompanied by a rise in the C-reactive protein level. Resumption of aspirin at a dose of 81 mg per day (a dose that preferentially targets COX-1) maintained blood counts; however, joint stiffness persisted and ESR remained elevated. An intermediate aspirin dose (162 mg per day) normalized inflammatory markers and improved fatigue and joint stiffness. Sixteen months after the initiation of therapy, the patient maintained normal blood counts and inflammatory markers on a daily dose of 162 mg of aspirin.

Patient 2 had a rapid improvement of hemoglobin, platelet count, and ESR within 1 month of receiving ibuprofen at a dose of 30 mg/kg per day, given in divided doses (Figure 1E). To reduce the risk of potential adverse events, the ibuprofen dose was reduced to 10 mg/kg per day. Nineteen months after initiation of therapy, the patient maintained hemoglobin level at 10.6-11.5 g/dL and ESR at 40 to 60 mm/h.

Because loss of TBXAS1 leads to the accumulation of its upstream substrate PGH₂, which can be processed by synthases to other PGs (Figure 1A), our findings of absent thromboxane A2 metabolite and increased accumulation of downstream urinary PG metabolites PG D metabolite (PGDM), PGEM, and PGIM in both patients could be expected (Figure 2A-C). The response to NSAIDs, which inhibit PGH₂ formation by inhibiting COX upstream, implies that patients with Ghosal hematodiaphyseal dysplasia syndrome also have an accumulation of the upstream AA substrate. Increased AA, in turn, can augment biosynthesis of not only the proinflammatory PGs PGE₂, PGD₂, and PGI₂ but also of the proinflammatory lipoxygenase products, reflected by 5-hydroxyeicosatetraenoic acid(5-HETE) and leukotriene E_4 (LTE₄) (Figure 2D-G). The higher doses of the NSAIDs also reduced biosynthesis of the lipoxygenase products of AA along with the PGs, normalizing hematologic and inflammatory parameters. Lower doses of aspirin and ibuprofen showed a less impressive reduction of the augmented eicosanoids, consistent with their less effective inhibition of COX-2, the dominant source of inflammatory PG formation.

Taken together, our results indicate that full or intermediatedose NSAIDs, at doses inhibitory to COX-2, are most effective at normalizing both hematologic parameters and inflammatory markers. Low-dose NSAIDs are sufficient for clinical hematologic improvement but do not fully inhibit excess eicosanoid accumulation and do not normalize inflammatory markers. Future studies are needed to determine whether complete inhibition of elevated eicosanoids with full-dose NSAIDs improves long-term patient outcomes compared with partial eicosanoid inhibition with lower-dose NSAIDs.



Figure 2. Mass spectrometry analysis of 24-hour urinary metabolites performed throughout therapy for 2 patients with Ghosal hematodiaphyseal dysplasia syndrome. Measurements of the urinary prostaglandin metabolites PGEM, PGDM, and PGIM are shown in panels A (for patient 1) and B (for patient 2). (C) The urinary metabolite of thromboxane A2 (TXM, 11-dehydrothromboxane B2 [9 α ,15S-dihydroxy-11-oxothromba-5Z,13E-dien-1-oic acid]). No TXM signal was detected in the patients' urine samples. Daily productions of TXM in adult and child healthy controls were 504 ± 1 and 107 ± 3 ng/d, respectively. The urinary levels of LTE₄ are shown in panels D for



Figure 2 (continued) case 1 and E for case 2. The urinary levels of 5-HETE are in panels F for case 1 and G for case 2. In each plot, the bar represents a mean ± standard deviation, for 3 replicate measurements, with statistical analysis indicated by the bar above, performed by one-way ANOVA. Red bars show urinary metabolites that were measured off therapy. Green bars show the metabolite levels on COX1/2 inhibitor therapy. Urinary metabolites for a control subject, age-matched for each patient are shown by the blue bars. (H) The results of eicosanoid metabolite analysis from A-F are summarized in the schematic diagram of AA metabolism, showing the aberrant accumulation of PGDM, PGEM, PGIM, 5-HETE and LTE4 in Ghosal hematodiaphyseal dysplasia syndrome (upward red arrows). In Ghosal hematodiaphyseal dysplasia syndrome, TBXAS1 is inactive (red line), preventing the conversion of PGH₂ to TXA₂ and downstream conversion to TXB₂ and TXM. (I) Inhibition of COX-1/2 by NSAIDs (yellow box). *P < .05, **P < .01, ***P < .001, and ****P < .0001.

Т

Much literature exists regarding the effect of eicosanoids on hematopoiesis, with the role of individual metabolites in hematopoiesis incompletely defined, with some evidence for opposing effects of PGs on stem cells and progenitor cells.¹⁴⁻¹⁸ Although our study does not identify the precise locus of eicosanoid effects on hematopoietic production in the Ghosal hematodiaphyseal dysplasia syndrome, our results demonstrate that impaired hematopoiesis and various cytopenia in patients with Ghosal hematodiaphyseal dysplasia syndrome were likely mediated by prostaglandins and leukotrienes and were entirely reversed by NSAIDs. The most commonly reported bone marrow disorders in Ghosal hematodiaphyseal dysplasia syndrome are hypocellularity, with reduced but normally maturing erythroid lineage, and marrow fibrosis.^{19,20} The hematopoietic dysfunction in Ghosal hematodiaphyseal dysplasia syndrome is thus reminiscent of autoimmune myelofibrosis, which can occur in inflammatory conditions, and results in hypoproliferative anemia that is typically responsive to corticosteroids.²¹

Pharmacological inhibitors of TBXAS1 were developed to treat thrombosis, but their efficacy was limited by the accumulation of PGH₂, which can also activate the thromboxane receptor.²²⁻²⁴ The combination of TBXAS1 inhibitors with thromboxane receptor antagonists blunts this effect, revealing an antithrombotic efficacy that is augmented by increased formation of the platelet inhibitor, PGI₂. In line with our observations in Ghosal hematodiaphyseal dysplasia syndrome, aspirin abolished the antithrombotic efficacy of this drug combination in dogs, consistent with TBXAS1 inhibition causing the accumulation of not merely PGH₂ but also AA.²⁵ In patients treated with TBXAS1 inhibitors, cytopenia analogous to Ghosal hematodiaphyseal dysplasia syndrome have not been reported.

In conclusion, our study shows that higher-dose NSAIDs can normalize hematologic parameters and serum inflammatory markers in patients with Ghosal hematodiaphyseal dysplasia syndrome. Our results demonstratefor the first time, to the best of our knowledge, that eicosanoid biosynthesis, which spans both PG and leukotriene formation, is augmented in patients with Ghosal hematodiaphyseal dysplasia syndrome and is responsive to treatment with aspirin and ibuprofen. Our data suggest that NSAIDs, which have a favorable side-effect profile compared with corticosteroids, should be considered as a first-line treatment for Ghosal hematodiaphyseal dysplasia syndrome.

Acknowledgments

The authors thank the patients and their families for participating in this study.

REFERENCES

- Ghosal SP, Mukherjee AK, Mukherjee D, Ghosh AK. Diaphyseal dysplasia associated with anemia. J Pediatr. 1988;113(1):49-57.
- Geneviève D, Proulle V, Isidor B, et al. Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome). Nat Genet. 2008;40(3): 284-286.
- 3. Kim SY, Ing A, Gong S, Yap KL, Bhat R. Novel compound heterozygous variants of *TBXAS1*

This work was supported by the National Institutes of Health (grant T32CA009679 and L30CA274783) (T.J.B.), (grant R03HL160678-01), and (American Society of Hematology Scholar Awards) (D.V.B.). G.A.F. is the McNeil Professor of Translational Medicine and Therapeutics.

Authorship

Contribution: T.J.B. and N.B. analyzed clinical data; H.M. and E.R. performed mass spectroscopy analyses; H.M. performed statistical analyses of mass spectroscopy results; C.M. and A.D. participated in patient care and contributed critical insights for their diagnosis and management and performed critical literature review; J.Q. analyzed bone marrow histology; G.A.F. initiated the collaboration between the 2 centers, and analyzed and contributed critical insights for eicosanoid metabolite analysis; M.C. and D.V.B. oversaw the clinical care, diagnostic work-up, treatment of the patients, and the study; T.J.B. and D.V.B. synthesized all data and wrote the manuscript; and all authors edited and approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: T.J.B., 0000-0002-4843-4639; H.M., 0000-0003-2224-5431; D.V.B., 0000-0002-1745-0353.

Correspondence: Melanie Cotter, Children's Health Ireland at Temple Street/Crumlin, Dublin, Ireland; email: melanie.cotter@cuh.ie; and Daria V. Babushok, Biomedical Research Building, Room 808, 421 Curie Blvd, Philadelphia, PA 19104; email: daria.babushok@pennmedicine.upenn. edu.

Footnotes

Submitted 12 October 2022; accepted 4 December 2022; prepublished online on *Blood* First Edition 27 December 2022. https://doi.org/ 10.1182/blood.2022018667.

*T.J.B., N.B., and H.M. contributed equally to this study.

†M.C. and D.V.B. contributed equally to this study.

Data are available on request from the corresponding authors, Melanie Cotter (melanie.cotter@cuh.ie) and Daria V. Babushok (daria.babushok@pennmedicine.upenn.edu).

The online version of this article contains a data supplement.

There is a **Blood** Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

- presenting with Ghosal hematodiaphyseal dysplasia treated with steroids. *Mol. Genet. Genomic Med.* 2021;9(3).
- Joy P, Yoganathan S, Korula S, et al. Ghosal hematodiaphyseal dysplasia and response to corticosteroid therapy. Am J Med Genet. 2021;185(2):596-599.
- Arora R, Aggarwal S, Deme S. Ghosal hematodiaphyseal dysplasia—a concise review including an illustrative patient. *Skeletal Radiol.* 2015;44(3):447-450.
- Ciftciler R, Buyukasık Y, Saglam EA, Haznedaroglu IC. Ghosal hematodiaphyseal dysplasia with autoimmune anemia in two adult siblings. *Transfus Apher Sci.* 2019;58(4): 449-452.
- Jeevan A, Doyard M, Kabra M, Daire VC, Gupta N. Ghosal type hematodiaphyseal dysplasia. Indian Pediatr. 2016;53(4):347-348.
- Kini PG, Kumar S, Moideen A, Narain AT. Ghosal hemato-diaphyseal dysplasia: a rare variety of hypoplastic anemia with good

response to steroid therapy. Indian J Hematol Blood Transfus. 2018;34(1):181-182.

- 9. Shakiba M, Shamsian S, Malekzadeh H, Yasaei M. Ghosal hematodiaphyseal dysplasia: a case report. *IJHOSCR*. 2020.
- 10. Ghosal SP. An unusual bone dysplasia. Indian J Pediatr. 1957;118(24):359-368.
- Özsoyla S. High-dose intravenous methylprednisolone therapy for anemia associated with diaphyseal dysplasia. *J Pediatr.* 1989;114(5):904.
- 12. Sharma R, Sierra Potchanant E, Schwartz JE, Nalepa G. Chronic steroid-response pancytopenia and increased bone density due to thromboxane synthase deficiency. *Pediatr Blood Cancer*. 2018;65(1):e26777.
- FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. *Circulation*. 1983;67(6):1174-1177.
- Taniguchi S, Shibuya T, Harada M, Niho Y. Prostaglandin-mediated suppression of in vitro growth of erythroid progenitor cells. *Kidney Int.* 1989;36(4):712-718.
- Ortega JA, Dukes PP, Ma A, Shore NA, Malekzadeh MH. A clinical trial of

prostaglandin E2 to increase erythropoiesis in anemia of end stage renal disease. A preliminary report. *Prostaglandins Leukot Med.* 1984;14:411-416.

- Pelus L, Gentile P. In vivo modulation of myelopoiesis by prostaglandin E2. III. Induction of suppressor cells in marrow and spleen capable of mediating inhibition of CFU-GM proliferation. *Blood.* 1988;71(6):1633-1640.
- 17. Goessling W, North TE, Loewer S, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. *Cell.* 2009;136(6):1136-1147.
- Hagedorn EJ, Durand EM, Fast EM, Zon LI. Getting more for your marrow: boosting hematopoietic stem cell numbers with PGE2. Exp Cell Res. 2014;329(2):220-226.
- Mazaheri P, Nadkarni G, Lowe E, et al. Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia: Ghosal Hematodiaphyseal Dysplasia. *Pediatr Blood Cancer*. 2010;55(6):1187-1190.
- 20. Datta K, Karmakar M, Hira M, et al. Ghosal hematodiaphyseal dysplasia with myelofibrosis. *Indian J Pediatr.* 2013;80(12): 1050-1052.

- Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. *Am J Hematol.* 2003;72(1):8-12.
- 22. Vezza R, Mezzasoma A, Venditti G, Gresele P. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. *Thromb Haemost*. 2002;87(01):114-121.
- FitzGerald GA, Reilly IA, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. *Circulation*. 1985; 72(6):1194-1201.
- 24. Lorenz RL, Fischer S, Wober W, Wagner HA, Weber PC. Effects on prostanoid formation and pharmacokinetics of dazmegrel (UK-38, 485), a novel thromboxane synthase inhibitor, in man. *Biochem Pharmacol.* 1986;35(5): 761-766.
- 25. Fitzgerald DJ, Fragetta J, FitzGerald GA. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest. 1988;82(5):1708-1713.

© 2023 by The American Society of Hematology